1,6-dichlorohexane

Endpoint summary

Description of key information

The test item was tested for acute oral toxicity and for acute dermal toxicity. The test item revealed an oral LD50 approximately 2675 mg/kg bw in rats. The test item revealed a dermal LD50 greater 2000 mg/kg bw in rats.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

LD50

Value:

2 675 mg/kg bw

Quality of whole database:

scientifically acceptable study report (Klimisch 2)

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Quality of whole database:

GLP and guideline study is available (Klimisch 1).

Additional information

-oral toxicity:

In an acute toxicity key study (BASF.1963) Bethesda-Black rats (5 per sex per dose) of both sexes were treated with 1,6-dichlorohexane (watery emulsion with traganth) in dose of 0.2, 1.6, 2.0, 2.5, 3.2 and 6.4 mL/kg (214, 1710, 2138, 2673, 3421, and 6842 mg/kg bw). Animals were observed for clinical signs for 7 days. Animals showed the following clinical signs: apathy, abdominal or lateral position, late mortalities. In higher dose (6.4 mL/kg; 6842 mg/kg bw) all animals died within 7 days. In all doses (beside dose of 1.6 mL/kg; 1710 mg/kg bw) animals died. A LD50 of 2675 mg/kg bw was determined.

-dermal toxicity:

In an acute toxicity key study (2012 -0182 -DGT) , 1,6-dichlorohexane was examined after a single dermal application to rats according to EU method B.3 and OECD guideline 402. One dose level of 2000 mg/kg bw was employed (limit test). One animal group of 10 rats (5 males and 5 females). A single dermal application of 2000 mg 1,6 -dichlorohexane/kg bw to rats did not reveal any clinical signs of toxicity. No influence on animal behaviour or premature death was noted. The body weight gain was not influenced by the test item administration. No skin reactions were observed at the application site.The macroscopic examination did not reveal any changes. Thus a LD50 over 2000 mg/kg bw was determined.

- inhalation toxicity:

In accordance with column 2 of REACH Annex VIII, the test acute toxicity after inhalation (required in section 8.5) does not need to be conducted as acute toxicity studies for oral and dermal application are available.

One inhalation study is available (Klimisch 4, BASF 1963). In the inhalation hazard test, 1,6-dichlorohexane was tested in 12 animals. The rats were exposed to an atmosphere saturated with vapour for about 8 hours. For saturation, air was conducted through a layer of about 5 cm of the product.No mortality and no clinical signs were observed.

Justification for selection of acute toxicity – oral endpoint
Only one key study is available.

Justification for selection of acute toxicity – dermal endpoint
Only one key study is available.

Justification for classification or non-classification

Acute oral toxicity:

Based on the results of the acute oral toxicity study, the substance was not classified and labelled according to Regulation (EC) No 1272/2008 (CLP) and Directive 67/548/EEC (DSD). The substance was classified and labelled as Cat 5 according to OECD GHS.

Acute dermal toxicity:

Based on the results of the acute dermal toxicity study, the substance was not classified and labelled according to Regulation (EC) No 1272/2008 (CLP) and Directive 67/548/EEC (DSD).